Remlifanserin clinical trials
Also written ACP-204.
How each study uses remlifanserin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the remlifanserin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ACP-204
- 4
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses remlifanserin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- ACP-204 in Adults With Alzheimer's Disease PsychosisRecruitingPhase 2/3ACADIA Pharmaceuticals Inc.NCT06159673Written as ACP-204
- ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyEnrolling by invitationPhase 3ACADIA Pharmaceuticals Inc.NCT06194799Written as ACP-204
- Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisRecruitingPhase 3ACADIA Pharmaceuticals Inc.NCT07095465Written as ACP-204
- Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia PsychosisRecruitingPhase 2ACADIA Pharmaceuticals Inc.NCT07029581Written as ACP-204
Codes
What other systems call remlifanserin · ClinicalTrials.gg INT016739
- UNII (FDA) H4L2AF2XB7REMLIFANSERINConfirmed FDA, Wikidata
- Wikidata Q133190166remlifanserinConfirmed FDA, Wikidata
- NCI Thesaurus C213400RemlifanserinOne source FDA
- DrugBank DB21707One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H4L2AF2XB7 | REMLIFANSERIN | Confirmed FDA, Wikidata |
| Wikidata | Q133190166 | remlifanserin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C213400 | Remlifanserin | One source FDA |
| DrugBank | DB21707 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.